Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study

CSL112 (Apolipoprotein A-I [Human]), an infusible, plasma-derived apolipoprotein A-I, is being developed to reduce cardiovascular events following acute myocardial infarction (AMI). A predecessor compound (CSL111) demonstrated a potential antiplatelet effect. A phase 2a multicentre, randomised, sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurbel, Paul A., Tantry, Udaya S., D’Andrea, Denise, Chung, Thomas, Alexander, John H., Bliden, Kevin P., Wright, Samuel D., Tricoci, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889770/
https://www.ncbi.nlm.nih.gov/pubmed/29582212
http://dx.doi.org/10.1007/s11239-018-1644-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889770/
https://www.ncbi.nlm.nih.gov/pubmed/29582212
http://dx.doi.org/10.1007/s11239-018-1644-z

Ejemplares similares